Supply of buprenorphine waivered physicians: the influence of state policies.

[1]  A. Schuchat.  DEPARTMENT OF HEALTH & HUMAN SERVICES , 2015 .

[2]  A. Hughes,et al.  State Estimates of Nonmedical Use of Prescription Pain Relievers , 2013 .

[3]  Carrie M. Farmer,et al.  The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. , 2012, Drug and alcohol dependence.

[4]  L. Dolovich,et al.  A Brief Overview of Academic Detailing in Canada: Another Role for Pharmacists , 2012, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[5]  J. Paradise,et al.  A Profile of Medicaid Managed Care Programs in 2010: Findings from a 50-State Survey , 2011 .

[6]  S. Brophy,et al.  Interventions for latent autoimmune diabetes (LADA) in adults. , 2011, The Cochrane database of systematic reviews.

[7]  R. Clark,et al.  The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. , 2011, Health affairs.

[8]  Alex H. S. Harris,et al.  Barriers to Use of Pharmacotherapy for Addiction Disorders and How to Overcome Them , 2011, Current psychiatry reports.

[9]  R. Clark,et al.  Factors associated with Medicaid patients' access to buprenorphine treatment. , 2011, Journal of substance abuse treatment.

[10]  H. Knudsen,et al.  Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. , 2011, Addictive behaviors.

[11]  J. Trafton,et al.  Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. , 2011, Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors.

[12]  L. Damschroder,et al.  A guiding framework and approach for implementation research in substance use disorders treatment. , 2011, Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors.

[13]  C. Schuster,et al.  Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. , 2010, Journal of substance abuse treatment.

[14]  W. Ling,et al.  From research to the real world: buprenorphine in the decade of the Clinical Trials Network. , 2010, Journal of substance abuse treatment.

[15]  E. Vicaut,et al.  Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. , 2010, Journal of substance abuse treatment.

[16]  A. Gordon,et al.  Physician Training is Never a Failure , 2009 .

[17]  R P Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2009, The Cochrane database of systematic reviews.

[18]  George Mendelson,et al.  Book Reviews , 1995 .

[19]  P. Barnett.  Comparison of costs and utilization among buprenorphine and methadone patients. , 2009, Addiction.

[20]  A. O'Malley,et al.  Do reimbursement delays discourage Medicaid participation by physicians? , 2008, Health affairs.

[21]  A. Gordon,et al.  Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. , 2008, The American journal on addictions.

[22]  P. Friedmann,et al.  Update in Addiction Medicine for the Primary Care Clinician , 2008, Journal of General Internal Medicine.

[23]  Jeremy Arkes,et al.  Why the DEA Stride Data are Still Useful for Understanding Drug Markets , 2008 .

[24]  Lori J. Ducharme,et al.  State policy influence on the early diffusion of buprenorphine in community treatment programs , 2008, Substance abuse treatment, prevention, and policy.

[25]  W. Klein-Schwartz,et al.  Toxicity of Buprenorphine Overdoses in Children , 2008, Pediatrics.

[26]  A. Gifford,et al.  Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years. , 2007, Drug and alcohol dependence.

[27]  C. Cunningham,et al.  Barriers to Obtaining Waivers to Prescribe Buprenorphine for Opioid Addiction Treatment Among HIV Physicians , 2007, Journal of General Internal Medicine.

[28]  D. Fiellin.  The First Three Years of Buprenorphine in the United States: Experience to Date and Future Directions , 2007, Journal of addiction medicine.

[29]  M. Connock,et al.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. , 2007, Health technology assessment.

[30]  Alison L. Koch,et al.  Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. , 2006, Drug and alcohol dependence.

[31]  M. Pantalon,et al.  Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. , 2006, The New England journal of medicine.

[32]  D. Litaker,et al.  Health care resource allocation and individuals' health care needs: examining the degree of fit. , 2005, Health policy.

[33]  P. O'Connor,et al.  The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? , 2005, Drug and alcohol dependence.

[34]  D. Litaker,et al.  Context and Healthcare Access: Looking Beyond the Individual , 2005, Medical care.

[35]  A. Harris,et al.  A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting , 2005, PharmacoEconomics.

[36]  Jason M. White,et al.  Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. , 2003, Drug and alcohol dependence.

[37]  W. Ling,et al.  Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. , 2003, The New England journal of medicine.

[38]  J. Hadley,et al.  The contribution of insurance coverage and community resources to reducing racial/ethnic disparities in access to care. , 2003, Health services research.

[39]  M. Heilig,et al.  1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial , 2003, The Lancet.

[40]  P. O'Connor,et al.  Clinical practice. Office-based treatment of opioid-dependent patients. , 2002, The New England journal of medicine.

[41]  J. Bell,et al.  SUBSTITUTION THERAPY FOR HEROIN ADDICTION , 2002, Substance use & misuse.

[42]  M. Brandeau,et al.  The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. , 2001, Addiction.

[43]  H. W. Clark,et al.  Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. , 2000, JAMA.

[44]  B. E. Carpenter,et al.  An analysis of the location decision of young primary care physicians , 1999 .

[45]  W. H. Hall,et al.  Effective medical treatment of opiate addiction , 1998 .

[46]  B. Rounsaville,et al.  A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. , 1998, The American journal of medicine.

[47]  S. Soumerai,et al.  Principles and Uses of Academic Detailing to Improve the Management of Psychiatric Disorders , 1998, International journal of psychiatry in medicine.

[48]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[49]  Alan Ross,et al.  The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome , 1991 .

[50]  P. O'Connor,et al.  Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. , 2009, Drug and Alcohol Dependence.

[51]  R P Mattick,et al.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. , 2008, The Cochrane database of systematic reviews.

[52]  T. Getzen,et al.  Economic and demographic trends signal an impending physician shortage. , 2002, Health affairs.

[53]  Eorge,et al.  A COMPARISON OF LEVOMETHADYL ACETATE , BUPRENORPHINE , AND METHADONE FOR OPIOID DEPENDENCE , 2000 .

[54]  Sidney D. Watson,et al.  Medicaid Physician Participation: Patients, Poverty, and Physician Self-Interest , 1995, American Journal of Law & Medicine.